“…Moreover, it was even longer than in results from the experimental and control arms of many studies [57] that have attempted to add another agent to standard chemotherapy, regardless of whether the agents were given simultaneously during front-line chemotherapy or during maintenance therapy after standard chemotherapy [10,11,12,57,58,59,60,61,62,63,64,65]. These adding agents have included antiangiogenic drugs, PARP inhibitors, immune system modulators, and many multitarget compounds that were used as upfront therapy [10,11,12,23,27,28,29,30,31,32,57,58,59,60,61,62,63,64,65].…”